These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 18091190

  • 1. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G.
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 4. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM.
    Ann Clin Psychiatry; 2007 Oct; 19(2):65-71. PubMed ID: 17612845
    [Abstract] [Full Text] [Related]

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [Abstract] [Full Text] [Related]

  • 6. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [Abstract] [Full Text] [Related]

  • 7. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA, Morrens M, Sabbe BG.
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
    Kissling W, Glue P, Medori R, Simpson S.
    Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA, Katsafouros K, Möller HJ, Medori R, Sacchetti E.
    J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
    [Abstract] [Full Text] [Related]

  • 16. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
    Macfadden W, Bossie CA, Turkoz I, Haskins JT.
    Int Clin Psychopharmacol; 2010 Mar; 25(2):75-82. PubMed ID: 20101185
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 18. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Int Clin Psychopharmacol; 2008 Nov 01; 23(6):325-31. PubMed ID: 18854720
    [Abstract] [Full Text] [Related]

  • 19. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.
    Hum Psychopharmacol; 2010 Jan 01; 25(1):37-46. PubMed ID: 20041474
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
    Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS.
    Eur Neuropsychopharmacol; 2005 Jan 01; 15(1):111-7. PubMed ID: 15572280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.